Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GABA puts a stop to pain.

L Jasmin1, M V Wu, P T Ohara

  • 1Department of Neurological Surgery, University of California, San Francisco, CA 94143-0112, USA.

Current Drug Targets. CNS and Neurological Disorders
|December 8, 2004
PubMed
Summary

A lack of inhibition from gamma-amino butyric acid (GABA) contributes to pain. New drugs targeting GABA pathways offer potential pain relief but face challenges with side effects and localized efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isolectin B4 (IB4)-conjugated streptavidin for the selective knockdown of proteins in IB4-positive (+) nociceptors.

bioRxiv : the preprint server for biology·2024
Same author

Gene regulation by gonadal hormone receptors underlies brain sex differences.

Nature·2022
Same author

BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities.

Translational psychiatry·2013
Same author

Cortical modulation of pain.

Cellular and molecular life sciences : CMLS·2004
Same author

Blockade of nociceptive inhibition of plasma extravasation by opioid stimulation of the periaqueductal gray and its interaction with vagus-induced inhibition in the rat.

Neuroscience·2003
Same author

Partial ablations of the flocculus and ventral paraflocculus in monkeys cause linked deficits in smooth pursuit eye movements and adaptive modification of the VOR.

Journal of neurophysiology·2002

Area of Science:

  • Neuroscience
  • Pharmacology
  • Pain Research

Background:

  • Pain states are often linked to reduced inhibition, particularly from gamma-amino butyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system (CNS).
  • Historically, GABA-acting drugs were mainly used for epilepsy, anxiety, and muscle spasms, with limited application in pain management.
  • Recent advancements have improved our understanding of GABA's role in pain circuitry, especially following nerve injury.

Purpose of the Study:

  • To explore the development of novel analgesic compounds targeting the GABAergic system.
  • To investigate strategies for overcoming the limitations of current systemically administered GABAergic drugs.
  • To highlight the potential of new drug targets and delivery systems for pain treatment.

Main Methods:

  • Development of analgesic compounds targeting GABA transporters, enzymes, and receptors.
  • Investigation of GABA analogs that inhibit ion channels for analgesic effects.
  • Exploration of advanced drug delivery systems like intrathecal pumps and viral vectors.

Main Results:

  • New analgesic compounds are being developed that specifically target components of the GABAergic system.
  • GABA analogs demonstrate analgesic properties through mechanisms like ion channel inhibition.
  • Challenges remain regarding systemic side effects and the dual role of GABA in pain modulation.

Conclusions:

  • Targeting specific GABA receptor subtypes and transporters offers a promising avenue for developing effective analgesics.
  • Advanced delivery systems are crucial for achieving localized therapeutic effects and minimizing systemic adverse events.
  • Future strategies focus on precise targeting within the nervous system to maximize pain relief and reduce side effects.

Related Experiment Videos